We are inching closer to a treatment for nonobstructive hypertrophic cardiomyopathy after Cytokinetics presented the full results from the ACACIA-HCM trial, showing that its cardiac myosin inhibitor, MYQORZO (aficamten), meaningfully improves how nHCM patients feel and function. ACACIA-HCM’s design focused on two parallel primary endpoints that measured both symptom burden and exercise capacity at 36 […] The post The Full Picture Clarifies Aficamten’s Impact on nHCM appeared first on Cardiac Wire .